Get started
Work

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

Year: 2022
Type: article
Study design: Observational Study
Abstract: The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.
DOI: 10.1038/s41698-022-00267-7
Institutions: Cleveland Clinic, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,390
Awards: G2665966410, G2992418894, Elucidating genetics of response to immune checkpoint blockade in lung cancer, G4102770861, G4266131079, G6403603385, Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance, G874817191, G9000003249, G9000303076, Cancer Center Support Grant
OpenAlex ID: W4224313453
FWCI: 3.972
Cites: 24
Cited by: 43
Related to: 10